Sign in to view content

Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity

Rishi P. Singh, MD

Video
Published 2024

Related

GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Characterization of Eyes With Geographic Atrophy That Developed Macular Neovascularization in the GATHER Clinical Trials
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2024
Anti-VEGF Resistant Subretinal Fluid Associated With Reduced Risk of Macular Atrophy and Better Vision: Drug-Induced Choroidal New Vessel Homeostasis?
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2020

Category: AMD-Non-Neovascular

See more